

Editorial

The Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and its absolute commitment to ethics and absence of conflicts of interest



Carmino Antonio de Souza ^{a,b,*}, Eduardo Magalhães Rego^{a,c},
Glaciano Nogueira Ribeiro^{a,d}, Sílvia Maria Meira Magalhães^{a,e},
Celso Arrais Rodrigues da Silva^{a,f}, Leny Nascimento da Motta Passos^{a,g},
Dimas Tadeu Covas^{a,h}, Renato Sampaio Tavares^{a,i},
Vania T.de Moraes Hungria^{a,j}, Edvan de Queiroz Crusóe^{a,k},
José Francisco Comenalli Marques Jr.^{a,b}, Carlos Sérgio Chiattoni^{a,l},
Dante Langhi Junior^{a,m}, Jorge Vaz Pinto Neto^{a,n}, Violete Petitto Laforga^{a,o},
Angelo Maiolino^{a,p}

^a Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH), São Paulo, SP, Brazil

^b Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil

^c Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

^d Hospital das Clínicas, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil

^e Universidade Federal do Ceará (UFC), Fortaleza, CE, Brazil

^f Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

^g Fundação de Hematologia e Hemoterapia do Amazonas (HEMOAM), Manaus, AM, Brazil

^h Hemocentro de Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil

ⁱ Hospital das Clínicas da Universidade Federal de Goiás (HC UFG), Goiânia, GO, Brazil

^j Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil

^k Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil

^l Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil

^m Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

ⁿ Centro de Câncer de Brasília (CETTRO), Brasília, DF, Brazil

^o Centro de Hematologia e Hemoterapia do Paraná (Hemepar), Curitiba, PR, Brazil

^p Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil

ARTICLE INFO

Article history:

Available online 26 May 2024

* Corresponding author at: Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil.

E-mail address: carmino@unicamp.br (C.A. de Souza).

<https://doi.org/10.1016/j.htct.2024.05.003>

2531-1379/© 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The Brazilian Association of Hematology, Hemotherapy, and Cell Therapy (ABHH) serves as the representative institution of the Brazilian Medical Association (AMB), entrusted with overseeing one of the most crucial medical specialties and bearing increasing responsibilities in advancing the well-being of both our patients and professionals in the field. The ongoing scientific advances within our extensive domain have needed ABHH to not only fulfill its institutional, managerial, legal, representative, and corporate duties but also to establish a method of operation for organizing and harmonizing all endeavors across scientific, educational, regulatory, ethical, and behavioral realms. Therefore, through the decision of its board and deliberative council, ABHH aims to publicly disclose its compliance policy.¹

ABHH is committed to transparently reaffirming its statutory goals and the principles articulated in its 'Code of Ethics and Conduct,' ensuring their application to directors, members, collaborators, and affiliated associated parties. Upholding the moral and ethical integrity of its leadership, ABHH respects both the Federal Constitution and all national legal frameworks, along with Codes of Ethics and Professional Conduct. Furthermore, it acknowledges and respects foreign legislation, particularly when it aligns with the foundational principles of the Brazilian legal system.

In alignment with these principles, ABHH mandates that its leadership and all those institutionally involved adhere to consistent standards of conduct, mitigating risks that may lead to conflicts of interest and tangible or intangible harm. Acting with integrity, ABHH prioritizes honesty, loyalty, and trust in all endeavors, driving scientific research, the pursuit of new technologies, data sharing, professional empowerment, and societal advancement, especially for patients.

Transparency and responsibility guide ABHH's interactions with the private and public sectors, ensuring

impartiality and fairness to all parties. Regardless of gender, race, color, or creed, ABHH fosters equity, extending equal care and attention to all. Demonstrating social responsibility, ABHH employs its resources to sustainably preserve its actions' impact.

ABHH unequivocally rejects any influence, advantage, or interest derived from illegal activities or situations that may compromise the integrity of its leaders, collaborators, or associated parties. Any potential conflict of interest, if identified, is subject to scrutiny and deliberation by ABHH's leadership, Ethics and Legislation Committee, ensuring transparency and accountability.

While secondary personal interests are not inherently inappropriate, ABHH recognizes the need to address conflicts that may impede its primary institutional goals. Mandatory declaration of conflicts, including in contractual agreements, serves to safeguard all stakeholders and reaffirm leadership integrity. ABHH remains committed to regular review and adaptation of its Compliance Policy, integrating relevant laws, and ensuring alignment with its guiding principles and values through transparent and inclusive processes.

Conflicts of interest

None.

REFERENCE

1. Ruble JH. Tools for "decloaking" the elephant in the room: conflict of interest, shared decision-making, and patient-centered care. *J Pain Palliat Care Pharmacother*. 2015;29(2):173–7. <https://doi.org/10.3109/15360288.2015.1037519>. PMID: 26095491.